ZA200204969B - Novel indole derivatives. - Google Patents
Novel indole derivatives. Download PDFInfo
- Publication number
- ZA200204969B ZA200204969B ZA200204969A ZA200204969A ZA200204969B ZA 200204969 B ZA200204969 B ZA 200204969B ZA 200204969 A ZA200204969 A ZA 200204969A ZA 200204969 A ZA200204969 A ZA 200204969A ZA 200204969 B ZA200204969 B ZA 200204969B
- Authority
- ZA
- South Africa
- Prior art keywords
- piperazin
- indole
- phenylsulfanyl
- phenoxy
- propyl
- Prior art date
Links
- 150000002475 indoles Chemical class 0.000 title description 6
- 229940054051 antipsychotic indole derivative Drugs 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 48
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 26
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 15
- -1 hydroxy, formyl Chemical group 0.000 claims description 14
- 239000003446 ligand Substances 0.000 claims description 14
- 229960003638 dopamine Drugs 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 125000002252 acyl group Chemical group 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 5
- 208000025966 Neurological disease Diseases 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 208000037765 diseases and disorders Diseases 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 208000028017 Psychotic disease Diseases 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 208000019906 panic disease Diseases 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 3
- 208000019022 Mood disease Diseases 0.000 claims description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 3
- 206010041250 Social phobia Diseases 0.000 claims description 3
- 125000004442 acylamino group Chemical group 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- JYHGCUIXRPWVAR-UHFFFAOYSA-N 4-[4-[2-(4-fluorophenyl)sulfanylethyl]piperazin-1-yl]-1h-indole Chemical compound C1=CC(F)=CC=C1SCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 JYHGCUIXRPWVAR-UHFFFAOYSA-N 0.000 claims description 2
- 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- XVYPXKLVMOPHEJ-UHFFFAOYSA-N ClC=1C=C(C=CC1Cl)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.FC(C1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1)(F)F Chemical compound ClC=1C=C(C=CC1Cl)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.FC(C1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1)(F)F XVYPXKLVMOPHEJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- QCURJGKNSUMJLK-UHFFFAOYSA-N FC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F.BrC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F Chemical compound FC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F.BrC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F QCURJGKNSUMJLK-UHFFFAOYSA-N 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- BKDIWRARRMTWJE-UHFFFAOYSA-N 1-[3,5-difluoro-4-[3-[4-(1h-indol-4-yl)piperazin-1-yl]propoxy]phenyl]propan-1-one Chemical compound FC1=CC(C(=O)CC)=CC(F)=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 BKDIWRARRMTWJE-UHFFFAOYSA-N 0.000 claims 1
- DYMNLOXRYLTXGI-UHFFFAOYSA-N 3-chloro-4-[4-[4-(1h-indol-4-yl)piperazin-1-yl]butoxy]benzonitrile Chemical compound ClC1=CC(C#N)=CC=C1OCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 DYMNLOXRYLTXGI-UHFFFAOYSA-N 0.000 claims 1
- OLRTWZYUKXHEAC-UHFFFAOYSA-N 4-[4-[2-(3-chlorophenyl)sulfanylethyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=CC(SCCN2CCN(CC2)C=2C=3C=CNC=3C=CC=2)=C1 OLRTWZYUKXHEAC-UHFFFAOYSA-N 0.000 claims 1
- UQEFMXMIVKTFAE-UHFFFAOYSA-N 4-[4-[3-(3,4-dimethylphenyl)sulfanylpropyl]piperazin-1-yl]-1h-indole Chemical compound C1=C(C)C(C)=CC=C1SCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 UQEFMXMIVKTFAE-UHFFFAOYSA-N 0.000 claims 1
- UHBOJWLZGGPCJB-UHFFFAOYSA-N 4-[4-[3-(3-bromophenyl)sulfanylpropyl]piperazin-1-yl]-1H-indole 4-[4-[3-[4-(trifluoromethoxy)phenyl]sulfanylpropyl]piperazin-1-yl]-1H-indole Chemical compound BrC=1C=C(C=CC1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.FC(OC1=CC=C(C=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1)(F)F UHBOJWLZGGPCJB-UHFFFAOYSA-N 0.000 claims 1
- IMXGTWGIFMWAQJ-UHFFFAOYSA-N 4-[4-[4-(2,5-dichlorophenoxy)butyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=C(Cl)C(OCCCCN2CCN(CC2)C=2C=3C=CNC=3C=CC=2)=C1 IMXGTWGIFMWAQJ-UHFFFAOYSA-N 0.000 claims 1
- YJSOYQIULDLRHZ-UHFFFAOYSA-N 4-[4-[4-(2,6-dichloro-4-fluorophenoxy)butyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC(F)=CC(Cl)=C1OCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 YJSOYQIULDLRHZ-UHFFFAOYSA-N 0.000 claims 1
- DOGCUTINLVQGLM-UHFFFAOYSA-N 4-[4-[4-(2-chloro-6-methylphenyl)sulfanylbutyl]piperazin-1-yl]-1h-indole Chemical compound CC1=CC=CC(Cl)=C1SCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 DOGCUTINLVQGLM-UHFFFAOYSA-N 0.000 claims 1
- UYEMZRWXCBYHPZ-UHFFFAOYSA-N 4-[4-[4-(4-bromo-2,6-difluorophenoxy)butyl]piperazin-1-yl]-1h-indole Chemical compound FC1=CC(Br)=CC(F)=C1OCCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 UYEMZRWXCBYHPZ-UHFFFAOYSA-N 0.000 claims 1
- QDRCBXXMSMWRFI-UHFFFAOYSA-N BrC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1 Chemical compound BrC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1 QDRCBXXMSMWRFI-UHFFFAOYSA-N 0.000 claims 1
- QPYIHTQGLIGHFF-UHFFFAOYSA-N ClC1=C(C(=CC=C1)C)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F Chemical compound ClC1=C(C(=CC=C1)C)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F QPYIHTQGLIGHFF-UHFFFAOYSA-N 0.000 claims 1
- OMPGWIYKLBSFQO-UHFFFAOYSA-N ClC1=C(C=CC=C1Cl)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.CC1=C(C=CC(=C1)C)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound ClC1=C(C=CC=C1Cl)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.CC1=C(C=CC(=C1)C)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 OMPGWIYKLBSFQO-UHFFFAOYSA-N 0.000 claims 1
- RGCOZXFJTFMHGE-UHFFFAOYSA-N FC(C1=CC=C(C=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1)(F)F.COC=1C=C(C=CC1OC)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound FC(C1=CC=C(C=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1)(F)F.COC=1C=C(C=CC1OC)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 RGCOZXFJTFMHGE-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- 230000016571 aggressive behavior Effects 0.000 description 3
- 230000000561 anti-psychotic effect Effects 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 208000020016 psychiatric disease Diseases 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 230000000697 serotonin reuptake Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- HEXKYCZHRHOSFY-UHFFFAOYSA-N 4-[4-[2-(2,4-dimethylphenyl)sulfanylethyl]piperazin-1-yl]-1h-indole Chemical compound CC1=CC(C)=CC=C1SCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 HEXKYCZHRHOSFY-UHFFFAOYSA-N 0.000 description 1
- KZEWQGCRIGPUPL-UHFFFAOYSA-N 4-[4-[3-(2,4,6-tribromophenoxy)propyl]piperazin-1-yl]-1h-indole Chemical compound BrC1=CC(Br)=CC(Br)=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 KZEWQGCRIGPUPL-UHFFFAOYSA-N 0.000 description 1
- ZHVTYAWDPWFKPU-UHFFFAOYSA-N 4-[4-[3-(2-bromo-4,6-difluorophenoxy)propyl]piperazin-1-yl]-1h-indole Chemical compound BrC1=CC(F)=CC(F)=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 ZHVTYAWDPWFKPU-UHFFFAOYSA-N 0.000 description 1
- MKBUROAPEBUIKK-UHFFFAOYSA-N 4-[4-[3-(2-chlorophenoxy)propyl]piperazin-1-yl]-1h-indole Chemical compound ClC1=CC=CC=C1OCCCN1CCN(C=2C=3C=CNC=3C=CC=2)CC1 MKBUROAPEBUIKK-UHFFFAOYSA-N 0.000 description 1
- INIDCHLQRPEVNJ-UHFFFAOYSA-N 4-[4-[4-(2-methoxyphenoxy)butyl]piperazin-1-yl]-1H-indole 4-[4-[3-(2-propan-2-ylphenyl)sulfanylpropyl]piperazin-1-yl]-1H-indole Chemical compound COC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1.C(C)(C)C1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 INIDCHLQRPEVNJ-UHFFFAOYSA-N 0.000 description 1
- SKTFQHRVFFOHTQ-UHFFFAOYSA-N 8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 SKTFQHRVFFOHTQ-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- CLTGXJVCBSRZKL-UHFFFAOYSA-N BrC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C(=CC(=C1)F)Br.BrC1=CC(=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C(=C1)F)F Chemical compound BrC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C(=CC(=C1)F)Br.BrC1=CC(=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C(=C1)F)F CLTGXJVCBSRZKL-UHFFFAOYSA-N 0.000 description 1
- ZKEWPPMKIIOOGR-UHFFFAOYSA-N BrC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1.BrC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound BrC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1.BrC1=C(C=CC=C1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 ZKEWPPMKIIOOGR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- KYACJQSTBUDANI-UHFFFAOYSA-N C1(=CC=CC=C1)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.C(C)C1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1.CC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)C Chemical compound C1(=CC=CC=C1)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.C(C)C1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC=C1.CC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)C KYACJQSTBUDANI-UHFFFAOYSA-N 0.000 description 1
- ZXWCDGHHUZGAKG-UHFFFAOYSA-N CC1=C(C(=CC=C1)C)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.CC1=C(OCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C(=CC=C1)C Chemical compound CC1=C(C(=CC=C1)C)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.CC1=C(OCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C(=CC=C1)C ZXWCDGHHUZGAKG-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- OOANGVGKKLXOMU-UHFFFAOYSA-N ClC1=C(C=C(C=C1)Cl)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=C(C=C1)C Chemical compound ClC1=C(C=C(C=C1)Cl)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC1=C(OCCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=C(C=C1)C OOANGVGKKLXOMU-UHFFFAOYSA-N 0.000 description 1
- SUOIKQLYFVXZGG-UHFFFAOYSA-N ClC1=C(C=CC=C1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC=1C=C(C=CC1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound ClC1=C(C=CC=C1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC=1C=C(C=CC1)SCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 SUOIKQLYFVXZGG-UHFFFAOYSA-N 0.000 description 1
- NCTSDWBLJQJWSM-UHFFFAOYSA-N ClC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F.ClC1=C(C(=CC=C1)Cl)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound ClC1=C(OCCCN2CCN(CC2)C2=C3C=CNC3=CC=C2)C=CC(=C1)F.ClC1=C(C(=CC=C1)Cl)SCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 NCTSDWBLJQJWSM-UHFFFAOYSA-N 0.000 description 1
- DXQNUDRSVKAIOH-UHFFFAOYSA-N ClC=1C=C(C#N)C=CC1OCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC=1C=C(C=CC1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 Chemical compound ClC=1C=C(C#N)C=CC1OCCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1.ClC=1C=C(C=CC1)SCCCN1CCN(CC1)C1=C2C=CNC2=CC=C1 DXQNUDRSVKAIOH-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010001584 alcohol abuse Diseases 0.000 description 1
- 208000025746 alcohol use disease Diseases 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 125000005129 aryl carbonyl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199901889 | 1999-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200204969B true ZA200204969B (en) | 2003-09-22 |
Family
ID=8108836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200204969A ZA200204969B (en) | 1999-12-30 | 2002-06-20 | Novel indole derivatives. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20030050307A1 (ja) |
| EP (1) | EP1246818A1 (ja) |
| JP (1) | JP2003519226A (ja) |
| KR (1) | KR20020063288A (ja) |
| CN (1) | CN1437598A (ja) |
| AR (1) | AR027134A1 (ja) |
| AU (1) | AU2352101A (ja) |
| BG (1) | BG106937A (ja) |
| BR (1) | BR0016955A (ja) |
| CA (1) | CA2395606A1 (ja) |
| CZ (1) | CZ20022489A3 (ja) |
| EA (1) | EA200200727A1 (ja) |
| HU (1) | HUP0203767A3 (ja) |
| IL (1) | IL150336A0 (ja) |
| IS (1) | IS6434A (ja) |
| MX (1) | MXPA02006498A (ja) |
| NO (1) | NO20023148L (ja) |
| NZ (1) | NZ519648A (ja) |
| PL (1) | PL355538A1 (ja) |
| SK (1) | SK9452002A3 (ja) |
| TR (1) | TR200201689T2 (ja) |
| WO (1) | WO2001049680A1 (ja) |
| ZA (1) | ZA200204969B (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002243394A1 (en) | 2000-11-16 | 2002-06-24 | Wyeth | Aryloxy piperidinyl derivatives for the treatment of depression |
| US6656950B2 (en) | 2001-04-25 | 2003-12-02 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine |
| CA2451229C (en) * | 2001-06-29 | 2009-02-10 | H. Lundbeck A/S | Indole derivatives |
| ES2326078T3 (es) | 2002-08-22 | 2009-09-30 | Dainippon Sumitomo Pharma Co., Ltd. | Medicamento destinado al sindrome de la disfuncion de integracion. |
| CN1826338B (zh) | 2003-06-23 | 2011-07-13 | 大日本住友制药株式会社 | 老年性痴呆症治疗药 |
| US20070160537A1 (en) | 2004-02-20 | 2007-07-12 | Takeo Ishiyama | In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
| AR055203A1 (es) * | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
| JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
| US8258139B2 (en) | 2010-11-08 | 2012-09-04 | Dainippon Sumitomo Pharma Co., Ltd. | Method of treatment for mental disorders |
| PL395469A1 (pl) * | 2011-06-29 | 2013-01-07 | Adamed Spólka Z Ograniczona Odpowiedzialnoscia | Pochodne indoloamin do leczenia chorób osrodkowego ukladu nerwowego |
| CN116554145A (zh) * | 2022-01-29 | 2023-08-08 | 江苏恩华药业股份有限公司 | 芳烷基-4-(1h)吲哚基哌嗪衍生物、其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2567884B1 (fr) * | 1984-07-19 | 1987-03-06 | Roussel Uclaf | Nouveaux derives de l'indole, leur preparation, leur application comme medicaments et les compositions les renfermant |
| GB8830312D0 (en) * | 1988-12-28 | 1989-02-22 | Lundbeck & Co As H | Heterocyclic compounds |
| DK148392D0 (da) * | 1992-12-09 | 1992-12-09 | Lundbeck & Co As H | Heterocykliske forbindelser |
| EP0900792B1 (en) * | 1997-09-02 | 2003-10-29 | Duphar International Research B.V | Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists |
| CN1155567C (zh) * | 1998-04-29 | 2004-06-30 | 惠氏公司 | 抑制精神的吲哚基衍生物 |
-
2000
- 2000-12-28 AR ARP000106989A patent/AR027134A1/es not_active Application Discontinuation
- 2000-12-29 WO PCT/DK2000/000742 patent/WO2001049680A1/en not_active Application Discontinuation
- 2000-12-29 CZ CZ20022489A patent/CZ20022489A3/cs unknown
- 2000-12-29 CN CN00819204A patent/CN1437598A/zh active Pending
- 2000-12-29 IL IL15033600A patent/IL150336A0/xx unknown
- 2000-12-29 MX MXPA02006498A patent/MXPA02006498A/es unknown
- 2000-12-29 PL PL00355538A patent/PL355538A1/xx not_active Application Discontinuation
- 2000-12-29 NZ NZ519648A patent/NZ519648A/en not_active Application Discontinuation
- 2000-12-29 KR KR1020027008609A patent/KR20020063288A/ko not_active Application Discontinuation
- 2000-12-29 TR TR2002/01689T patent/TR200201689T2/xx unknown
- 2000-12-29 CA CA002395606A patent/CA2395606A1/en not_active Abandoned
- 2000-12-29 BR BR0016955-2A patent/BR0016955A/pt not_active IP Right Cessation
- 2000-12-29 SK SK945-2002A patent/SK9452002A3/sk unknown
- 2000-12-29 AU AU23521/01A patent/AU2352101A/en not_active Abandoned
- 2000-12-29 EA EA200200727A patent/EA200200727A1/ru unknown
- 2000-12-29 JP JP2001550220A patent/JP2003519226A/ja not_active Withdrawn
- 2000-12-29 EP EP00987207A patent/EP1246818A1/en not_active Withdrawn
- 2000-12-29 HU HU0203767A patent/HUP0203767A3/hu unknown
-
2002
- 2002-06-19 IS IS6434A patent/IS6434A/is unknown
- 2002-06-20 ZA ZA200204969A patent/ZA200204969B/en unknown
- 2002-06-25 US US10/183,961 patent/US20030050307A1/en not_active Abandoned
- 2002-06-28 NO NO20023148A patent/NO20023148L/no not_active Application Discontinuation
- 2002-07-22 BG BG106937A patent/BG106937A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20022489A3 (cs) | 2002-10-16 |
| NO20023148D0 (no) | 2002-06-28 |
| MXPA02006498A (es) | 2002-11-29 |
| HUP0203767A2 (hu) | 2003-03-28 |
| WO2001049680A1 (en) | 2001-07-12 |
| AU2352101A (en) | 2001-07-16 |
| BR0016955A (pt) | 2003-04-29 |
| IL150336A0 (en) | 2002-12-01 |
| US20030050307A1 (en) | 2003-03-13 |
| CN1437598A (zh) | 2003-08-20 |
| PL355538A1 (en) | 2004-05-04 |
| BG106937A (en) | 2003-04-30 |
| JP2003519226A (ja) | 2003-06-17 |
| NO20023148L (no) | 2002-06-28 |
| AR027134A1 (es) | 2003-03-12 |
| KR20020063288A (ko) | 2002-08-01 |
| NZ519648A (en) | 2004-05-28 |
| EA200200727A1 (ru) | 2002-12-26 |
| IS6434A (is) | 2002-06-19 |
| SK9452002A3 (en) | 2002-11-06 |
| TR200201689T2 (tr) | 2002-10-21 |
| EP1246818A1 (en) | 2002-10-09 |
| CA2395606A1 (en) | 2001-07-12 |
| HUP0203767A3 (en) | 2004-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007262426B2 (en) | Carbonylated (aza) cyclohexanes as dopamine D3 receptor ligands | |
| JP4400566B2 (ja) | ベンズアミド誘導体又はその塩 | |
| JPH09502431A (ja) | 治療薬剤としての二環式芳香族化合物 | |
| FR2567885A1 (fr) | Derives 3-aminopropoxyaryliques, leur preparation, leur application comme medicaments et compositions pharmaceutiques les contenant | |
| US7393845B2 (en) | Heteroaryl derivates, their preparation and use | |
| JP2003524571A (ja) | インドール−及び２，３−ジヒドロインドール誘導体、その製造方法及びその使用方法 | |
| ZA200204969B (en) | Novel indole derivatives. | |
| US20060264496A1 (en) | Substituted indoline and indole derivatives | |
| CN101743239A (zh) | 氰基异喹啉 | |
| JP2004516321A (ja) | 精神医学及び神経障害の治療に有用な３−インドリン誘導体 | |
| JP2003519224A (ja) | 置換されたフェニル−ピペラジン誘導体、その製造方法及びその使用方法 | |
| JP2009507052A (ja) | ピリミジン誘導体およびそのｋｃｎｑカリウムチャネル開口薬としての使用 | |
| ES2223628T3 (es) | Derivados de 4-fenil-1-piperazinilo, -piperidinilo y -tetrahidropiridilo. | |
| US6306859B1 (en) | N-substituted imide derivatives with serotonergic activity | |
| US20050148635A1 (en) | 3-imino-2-indolones for the treatment of depression and/or anxiety | |
| ZA200308848B (en) | Novel indole derivatives. | |
| JP6943239B2 (ja) | Ｋｃｎｑ２〜５チャネル活性化剤 | |
| CA2361182A1 (en) | N-substituted imide derivatives with serotonergic activity | |
| EP1751106B1 (en) | Piperazine derivatives of alkyl oxindoles | |
| CN101010296A (zh) | 烷基羟吲哚的哌嗪衍生物 | |
| JP2003519229A (ja) | 新規ヘテロアリール誘導体、その製造方法及びその使用方法 | |
| ZA200505031B (en) | 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahy-dropyridine derivatives as serotonin reuptake inhibitors | |
| JP3316214B2 (ja) | ５‐ｈｔ１ａ拮抗物質として有用な４‐アミノ‐２‐（ヘテロ）アリール‐ブタンアミド | |
| JPS6137765A (ja) | ３‐アミノプロポキシアリール誘導体 | |
| NZ541999A (en) | Substituted indoline and indole derivatives |